The global pancreatic cancer diagnostic market size was estimated at USD 2.80 billion in 2025 and is projected to reach USD 5.15 billion by 2033, growing at a CAGR of 6.83% from 2026 to 2033. The increasing prevalence of pancreatic cancer, the growing emphasis on early detection, and advancements in molecular diagnostics and imaging technologies are the key drivers of the global market.
In addition, the rising adoption of liquid biopsy and AI-assisted imaging, coupled with expanding healthcare infrastructure and oncology screening programs in emerging economies, is further supporting market growth. Pancreatic cancer is one of the leading causes of cancer-related death across the globe, and the burden of disease is escalating at a significant pace, driven by late-stage diagnosis and limited early detection options. According to the American Cancer Society’s Cancer Facts & Figures, published in January 2026, the five-year relative survival rate remains approximately 13%, underscoring the persistently poor prognosis of the disease. In 2026 alone, an estimated 67,530 new cases and 52,740 deaths are projected in the United States, making pancreatic cancer the third leading cause of cancer-related mortality despite accounting for only about 3% of all cancer diagnoses.
Notably, incidence has been increasing by nearly 1% annually since the 1990s. Only about 17% of patients are diagnosed at a localized stage, where the five-year survival rate is about 44%, whereas most cases are detected at advanced stages, with significantly lower survival. These trends highlight the urgent need for improved early detection and advanced diagnostic solutions.
Moreover, early disease diagnosis is critical to improving treatment outcomes. Consequently, market participants and healthcare organizations are increasingly investing in funding initiatives, awareness campaigns, and research programs to encourage routine checkups and screening practices. These strategic efforts are focused on enhancing early-stage detection rates, which remain comparatively low, and improving overall patient survival. Such initiatives are expected to support the advancement of diagnostic capabilities and drive growth in the pancreatic cancer diagnostics industry.
For instance, in November 2025, the Pancreatic Cancer Action Network announced new research grant investments to support scientists across multiple institutions in advancing early detection, addressing therapeutic resistance, and improving treatment outcomes for pancreatic cancer. These funding initiatives are specifically designed to bridge critical research gaps and accelerate innovation in diagnostic and therapeutic approaches.
The significant rise in the number of pancreatic malignancy cases is driving the adoption of screening tests and generating strong demand for novel diagnostic solutions. Currently, diagnostic modalities such as biomarker assays, liver function tests, biopsies, and advanced imaging technologies are widely utilized for disease detection. Moreover, the growing demand for advanced diagnostic solutions is prompting manufacturers to develop innovative, high-precision testing technologies. For instance, in March 2026, researchers supported by the National Institutes of Health developed a novel blood-based test combining multiple protein biomarkers that demonstrated over 90% accuracy in detecting pancreatic cancer, including early-stage cases, highlighting significant progress toward non-invasive early-detection solutions.
Moreover, the growing number of programs promoting screening for malignant tumors is driving worldwide demand for pancreatic cancer diagnostic products. Partnerships among organizations such as the World Health Organization, Centers for Disease Control and Prevention, and the Pancreatic Cancer Action Network are expected to support market growth by advancing awareness and diagnosis. In addition, multiple initiatives are encouraging early screening, risk assessment, and biomarker-based detection of pancreatic malignancies.
For instance, in October 2025, Pancreatic Cancer Action Network launched its Shine a Light campaign to raise awareness of early symptoms, risk factors, and the importance of timely diagnosis. Furthermore, global initiatives such as World Pancreatic Cancer Day 2025, which the World Pancreatic Cancer Coalition celebrated to mark 10 years of driving global awareness, have significantly increased awareness of symptoms, genetic testing, and diagnostic pathways, thereby accelerating the adoption of pancreatic cancer diagnostic technologies worldwide.
Advancements in molecular diagnostics are creating significant growth opportunities in the pancreatic cancer diagnostics industry. Molecular diagnostic tests enable the identification of specific genetic mutations and biomarkers associated with pancreatic malignancies, facilitating earlier diagnosis and more targeted treatment approaches. For example, liquid biopsy-based tests that detect circulating tumor DNA (ctDNA) are increasingly being developed and validated to support early-stage detection of pancreatic cancer.
Moreover, the integration of artificial intelligence (AI) in imaging, pathology, and biomarker-based testing is expected to enhance early diagnostic accuracy and efficiency. Recent studies published in September 2024 in leading gastroenterology and oncology journals highlight that AI-assisted endoscopic ultrasound and biomarker analysis demonstrate improved sensitivity in detecting early pancreatic lesions compared to conventional diagnostic methods, thereby supporting increased adoption of advanced diagnostic technologies.
This product will be delivered within 1-3 business days.
In addition, the rising adoption of liquid biopsy and AI-assisted imaging, coupled with expanding healthcare infrastructure and oncology screening programs in emerging economies, is further supporting market growth. Pancreatic cancer is one of the leading causes of cancer-related death across the globe, and the burden of disease is escalating at a significant pace, driven by late-stage diagnosis and limited early detection options. According to the American Cancer Society’s Cancer Facts & Figures, published in January 2026, the five-year relative survival rate remains approximately 13%, underscoring the persistently poor prognosis of the disease. In 2026 alone, an estimated 67,530 new cases and 52,740 deaths are projected in the United States, making pancreatic cancer the third leading cause of cancer-related mortality despite accounting for only about 3% of all cancer diagnoses.
Notably, incidence has been increasing by nearly 1% annually since the 1990s. Only about 17% of patients are diagnosed at a localized stage, where the five-year survival rate is about 44%, whereas most cases are detected at advanced stages, with significantly lower survival. These trends highlight the urgent need for improved early detection and advanced diagnostic solutions.
Moreover, early disease diagnosis is critical to improving treatment outcomes. Consequently, market participants and healthcare organizations are increasingly investing in funding initiatives, awareness campaigns, and research programs to encourage routine checkups and screening practices. These strategic efforts are focused on enhancing early-stage detection rates, which remain comparatively low, and improving overall patient survival. Such initiatives are expected to support the advancement of diagnostic capabilities and drive growth in the pancreatic cancer diagnostics industry.
For instance, in November 2025, the Pancreatic Cancer Action Network announced new research grant investments to support scientists across multiple institutions in advancing early detection, addressing therapeutic resistance, and improving treatment outcomes for pancreatic cancer. These funding initiatives are specifically designed to bridge critical research gaps and accelerate innovation in diagnostic and therapeutic approaches.
The significant rise in the number of pancreatic malignancy cases is driving the adoption of screening tests and generating strong demand for novel diagnostic solutions. Currently, diagnostic modalities such as biomarker assays, liver function tests, biopsies, and advanced imaging technologies are widely utilized for disease detection. Moreover, the growing demand for advanced diagnostic solutions is prompting manufacturers to develop innovative, high-precision testing technologies. For instance, in March 2026, researchers supported by the National Institutes of Health developed a novel blood-based test combining multiple protein biomarkers that demonstrated over 90% accuracy in detecting pancreatic cancer, including early-stage cases, highlighting significant progress toward non-invasive early-detection solutions.
Moreover, the growing number of programs promoting screening for malignant tumors is driving worldwide demand for pancreatic cancer diagnostic products. Partnerships among organizations such as the World Health Organization, Centers for Disease Control and Prevention, and the Pancreatic Cancer Action Network are expected to support market growth by advancing awareness and diagnosis. In addition, multiple initiatives are encouraging early screening, risk assessment, and biomarker-based detection of pancreatic malignancies.
For instance, in October 2025, Pancreatic Cancer Action Network launched its Shine a Light campaign to raise awareness of early symptoms, risk factors, and the importance of timely diagnosis. Furthermore, global initiatives such as World Pancreatic Cancer Day 2025, which the World Pancreatic Cancer Coalition celebrated to mark 10 years of driving global awareness, have significantly increased awareness of symptoms, genetic testing, and diagnostic pathways, thereby accelerating the adoption of pancreatic cancer diagnostic technologies worldwide.
Advancements in molecular diagnostics are creating significant growth opportunities in the pancreatic cancer diagnostics industry. Molecular diagnostic tests enable the identification of specific genetic mutations and biomarkers associated with pancreatic malignancies, facilitating earlier diagnosis and more targeted treatment approaches. For example, liquid biopsy-based tests that detect circulating tumor DNA (ctDNA) are increasingly being developed and validated to support early-stage detection of pancreatic cancer.
Moreover, the integration of artificial intelligence (AI) in imaging, pathology, and biomarker-based testing is expected to enhance early diagnostic accuracy and efficiency. Recent studies published in September 2024 in leading gastroenterology and oncology journals highlight that AI-assisted endoscopic ultrasound and biomarker analysis demonstrate improved sensitivity in detecting early pancreatic lesions compared to conventional diagnostic methods, thereby supporting increased adoption of advanced diagnostic technologies.
Global Pancreatic Cancer Diagnostic Market Report Segmentation
This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, the analyst has segmented the global pancreatic cancer diagnostic market report based on the product, test type, cancer type, end use, and regions.Product Outlook (Revenue, USD Million, 2021-2033)
- Instruments
- Consumables
- Services
Application Outlook (Revenue, USD Million, 2021-2033)
- Imaging Test
- CT Scan
- MRI
- Ultrasound
- PET
- Others
- Biopsy
- Blood Test
- Liver Function Tests
- Tumor Markers
- Others
- Others
Cancer Type Outlook (Revenue, USD Million, 2021-2033)
- Exocrine
- Adenocarcinoma
- Squamous Cell Carcinoma
- Adenosquamous Carcinoma
- Colloid Carcinoma
- Endocrine
End Use Outlook (Revenue, USD Million, 2021-2033)
- Hospitals
- Clinics
- Laboratories
- Others
Regional Outlook (Revenue, USD Million, 2021-2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- China
- Japan
- India
- Australia
- Thailand
- South Korea
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Pancreatic Cancer Diagnostic Market Variables, Trends & Scope
Chapter 4. Pancreatic Cancer Diagnostic Market Segment Analysis, by Product, 2021-2033 (USD Million)
Chapter 5. Pancreatic Cancer Diagnostic Market Segment Analysis, by Test Type 2021-2033 (USD Million)
Chapter 6. Pancreatic Cancer Diagnostic Market Segment Analysis, by Cancer Type, 2021-2033 (USD Million)
Chapter 7. Pancreatic Cancer Diagnostic Market Segment Analysis, by End Use, 2021-2033 (USD Million)
Chapter 8. Pancreatic Cancer Diagnostic Market: Regional Estimates & Trend Analysis
Chapter 9. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Thermo Fisher Scientific, Inc.
- QIAGEN
- Illumina, Inc.
- F. Hoffmann-La Roche Ltd.
- BD
- Agilent Technologies, Inc.
- Myriad Genetics, Inc
- Koninklijke Philips N.V.
- Abbott
- Hitachi, Ltd
- Danaher
- Prestige Biopharma Ltd
- BioMarker Strategies
- ASURAGEN, INC
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | April 2026 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 2.8 Billion |
| Forecasted Market Value ( USD | $ 5.15 Billion |
| Compound Annual Growth Rate | 6.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 14 |
